Meeting to be held on February 14 hosted by Oppenheimer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target lowered to $163 from $165 at Guggenheim
- Neurocrine Biosciences’ Earnings Call: Record Sales & Strategic Growth
- Neurocrine price target lowered to $148 from $154 at RBC Capital
- Neurocrine price target lowered to $147 from $157 at Wedbush
- Hold Rating on Neurocrine Due to Below-Expectations Financial Performance and Conservative Sales Guidance